- Home
- OAKU vs LCTX Comparison
OAKU vs LCTX Comparison
Compare OAKU & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OAKU
- LCTX
- Stock Information
- Founded
- OAKU 2022
- LCTX 1990
- Country
- OAKU Canada
- LCTX United States
- Employees
- OAKU N/A
- LCTX N/A
- Industry
- OAKU Blank Checks
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OAKU Finance
- LCTX Health Care
- Exchange
- OAKU Nasdaq
- LCTX Nasdaq
- Market Cap
- OAKU N/A
- LCTX 95.2M
- IPO Year
- OAKU 2023
- LCTX N/A
- Fundamental
- Price
- OAKU $11.69
- LCTX $0.48
- Analyst Decision
- OAKU
- LCTX Strong Buy
- Analyst Count
- OAKU 0
- LCTX 5
- Target Price
- OAKU N/A
- LCTX $4.20
- AVG Volume (30 Days)
- OAKU 1.9K
- LCTX 879.3K
- Earning Date
- OAKU 01-01-0001
- LCTX 05-13-2025
- Dividend Yield
- OAKU N/A
- LCTX N/A
- EPS Growth
- OAKU N/A
- LCTX N/A
- EPS
- OAKU 0.03
- LCTX N/A
- Revenue
- OAKU N/A
- LCTX $9,499,000.00
- Revenue This Year
- OAKU N/A
- LCTX N/A
- Revenue Next Year
- OAKU N/A
- LCTX $232.66
- P/E Ratio
- OAKU $456.23
- LCTX N/A
- Revenue Growth
- OAKU N/A
- LCTX 6.19
- 52 Week Low
- OAKU $10.77
- LCTX $0.37
- 52 Week High
- OAKU $11.71
- LCTX $1.40
- Technical
- Relative Strength Index (RSI)
- OAKU 75.49
- LCTX 52.76
- Support Level
- OAKU $11.60
- LCTX $0.37
- Resistance Level
- OAKU $11.71
- LCTX $0.51
- Average True Range (ATR)
- OAKU 0.00
- LCTX 0.04
- MACD
- OAKU -0.00
- LCTX 0.00
- Stochastic Oscillator
- OAKU 0.00
- LCTX 73.64
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.